Defective CD8+ and CD4+ T‐cell function and increased regulatory T‐cell numbers have been described in CLL [10, 23], with several of these further exacerbated by existing treatment modalities, particularly the use of purine analogue, bendamustine combination, or alemtuzumab [5]. The gene discussed is CD8A; the disease is B-cell chronic lymphocytic leukemia.